GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
If you have been NEWLY DIAGNOSED START HERE
VIDEOS
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
ARTICLES
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.